Filtered By:
Infectious Disease: Hepatitis C
Drug: Insulin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Current level of evidence on causal association between Hepatitis C virus and type 2 diabetes: A review
Publication date: Available online 2 December 2016 Source:Journal of Advanced Research Author(s): Giacomo Gastaldi, Nicolas Goossens, Sophie Clément, Francesco Negro The association between hepatitis C virus (HCV) infection and type 2 diabetes (T2D) has been known for over 20 years. Cross-sectional and longitudinal studies have shown a higher prevalence and incidence, respectively, of T2D in patients with chronic HCV infection. HCV induces glucose metabolism alterations mostly interfering with the insulin signalling chain in hepatocytes, although extrahepatic mechanisms seem to contribute. Both IR and T2D accelerate the ...
Source: Journal of Advanced Research - December 2, 2016 Category: Research Source Type: research

Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010. Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news

Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms.
Abstract Hepatitis C virus (HCV) infection represents a major health issue worldwide due to its burden of chronic liver disease and extrahepatic manifestations including cardiovascular diseases, which are associated with excess mortality. Analysis of published studies supports the view that HCV infection should be considered a risk factor for the development of carotid atherosclerosis, heart failure and stroke. In contrast, findings from studies addressing coronary artery disease and HCV have yielded conflicting results. Therefore, meta-analytic reviews and prospective studies are warranted. The pathogenic mechani...
Source: World Journal of Gastroenterology : WJG - April 7, 2014 Category: Gastroenterology Authors: Adinolfi LE, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, Florio A, Loria P Tags: World J Gastroenterol Source Type: research

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
Conclusions: Antiviral treatment for HCV infection is associated with improved renal and cardiovascular outcomes in diabetic patients. (Hepatology 2013;)
Source: Hepatology - October 12, 2013 Category: Internal Medicine Authors: Yao‐Chun Hsu, Jaw‐Town Lin, Hsiu J. Ho, Yu‐Hsi Kao, Yen‐Tsung Huang, Nai‐Wan Hsiao, Ming‐Shiang Wu, Yi‐Ya Liu, Chun‐Ying Wu Tags: Original Source Type: research

Interferon‐based therapy reduces risk of stroke in chronic hepatitis C patients: a population‐based cohort study in Taiwan
ConclusionsInterferon‐based therapy may reduce the long‐term risk of stroke in patients with chronic HCV infection.
Source: Alimentary Pharmacology and Therapeutics - June 29, 2013 Category: Drugs & Pharmacology Authors: C.‐S. Hsu, J.‐H. Kao, Y.‐C. Chao, H. H. Lin, Y.‐C. Fan, C.‐J. Huang, P.‐S. Tsai Tags: Original Article Source Type: research

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research